Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
Alanine Transaminase
/ metabolism
Antioxidants
/ administration & dosage
Aspartate Aminotransferases
/ metabolism
Blood Glucose
/ metabolism
Cholesterol, LDL
Dietary Supplements
Humans
Leptin
/ metabolism
Liver
/ enzymology
Non-alcoholic Fatty Liver Disease
/ drug therapy
Oxidative Stress
Vitamin E
/ administration & dosage
NAFLD
NASH
Non-alcoholic fatty liver disease
Vitamin E
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
24
06
2020
accepted:
16
08
2020
pubmed:
19
8
2020
medline:
25
8
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Νon-alcoholic fatty liver disease (NAFLD) is estimated to be the most common cause of end-stage liver disease in the next years. Vitamin E has shown beneficial effects as a possible "scavenger" of oxidative stress products, which play a major role in pathogenesis of the disease. The purpose of the present meta-analysis is to investigate the effects of vitamin E supplementation in biochemical and histological parameters in adult patients with NAFLD. Literature search was performed in major electronic databases (MEDLINE, CENTRAL, and Embase) up to June 2020 for randomized clinical trials, which examined vitamin E versus placebo treatment in adults with NAFLD. Changes in liver enzymes were considered as primary outcomes while changes in histological, biochemical, and metabolic parameters as secondary. Quality of evidence was assessed through risk of bias according to the Cochrane risk of bias tool. Eight studies were included in qualitative analysis and seven in quantitative analysis. Vitamin E reduced the values of liver enzymes compared with placebo (-7.37 IU/L, 95% confidence interval: -10.11 to -4.64 for alanine aminotransferase, and -5.71 IU/L, 95% confidence interval: -9.49 to -1.93 for aspartate aminotransferase). Additionally, vitamin E improved statistically significantly liver pathology in every individual histological parameter as well as low-density lipoprotein cholesterol, fasting blood glucose, and serum leptin values. Vitamin E can improve biochemical and histological characteristics of NAFLD patients, especially of non-alcoholic steatohepatitis patients. The results indicate that vitamin E could be a promising choice and be considered as a treatment option in patients with NAFLD.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Νon-alcoholic fatty liver disease (NAFLD) is estimated to be the most common cause of end-stage liver disease in the next years. Vitamin E has shown beneficial effects as a possible "scavenger" of oxidative stress products, which play a major role in pathogenesis of the disease. The purpose of the present meta-analysis is to investigate the effects of vitamin E supplementation in biochemical and histological parameters in adult patients with NAFLD.
METHODS
METHODS
Literature search was performed in major electronic databases (MEDLINE, CENTRAL, and Embase) up to June 2020 for randomized clinical trials, which examined vitamin E versus placebo treatment in adults with NAFLD. Changes in liver enzymes were considered as primary outcomes while changes in histological, biochemical, and metabolic parameters as secondary. Quality of evidence was assessed through risk of bias according to the Cochrane risk of bias tool.
RESULTS
RESULTS
Eight studies were included in qualitative analysis and seven in quantitative analysis. Vitamin E reduced the values of liver enzymes compared with placebo (-7.37 IU/L, 95% confidence interval: -10.11 to -4.64 for alanine aminotransferase, and -5.71 IU/L, 95% confidence interval: -9.49 to -1.93 for aspartate aminotransferase). Additionally, vitamin E improved statistically significantly liver pathology in every individual histological parameter as well as low-density lipoprotein cholesterol, fasting blood glucose, and serum leptin values.
CONCLUSIONS
CONCLUSIONS
Vitamin E can improve biochemical and histological characteristics of NAFLD patients, especially of non-alcoholic steatohepatitis patients. The results indicate that vitamin E could be a promising choice and be considered as a treatment option in patients with NAFLD.
Substances chimiques
Antioxidants
0
Blood Glucose
0
Cholesterol, LDL
0
Leptin
0
Vitamin E
1406-18-4
Aspartate Aminotransferases
EC 2.6.1.1
Alanine Transaminase
EC 2.6.1.2
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
311-319Informations de copyright
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013/09/18 2013; 10: 686-690.
Marchesini G, Day CP, Dufour JF et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016 Jun; 64: 1388-1402.
Day CP, James OFW. Steatohepatitis: a tale of two “hits”? Gastroenterology. United States 1998; 114: 842-845.
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010/11/03 2010; 52: 1836-1846.
Sokol RJ, Balistreri WF, Hoofnagle JH, Jones EA. Vitamin E deficiency in adults with chronic liver disease. Am. J. Clin. Nutr. 1985; 41: 66-72. Available from. https://doi.org/10.1093/ajcn/41.1.66
Leo MA, Rosman AS, Lieber CS. Differential depletion of carotenoids and tocopherol in liver disease. Hepatology. 1993/06/01 1993; 17: 977-986.
Chalasani NP, Sanyal AJ, Kowdley KV et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp. Clin. Trials 2009 Jan; 30: 88-96.
Lavine JE, Schwimmer JB, Molleston JP et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp. Clin. Trials 2010 Jan; 31: 62-70.
Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad. Med. J. 2019 Nov; 95: 601-611.
Sato K, Gosho M, Yamamoto T et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutr. 2015; 31: 923-930. Available from:. https://doi.org/10.1016/j.nut.2014.11.018
Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int. J. Clin. Exp. Med. 2015; 8: 3924-3934.
Schwimmer JB, Behling C, Newbury R et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005/08/24 2005; 42: 641-649.
Brunt EM. Histological assessment of nonalcoholic fatty liver disease in adults and children. Clin. Liver Dis. 2012 Sep; 1: 108-111.
Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820. Available from. http://ovidsp.ovid.com/ovidweb.cgi?T=JS%26PAGE=reference%26D=emed12%26NEWS=N%26AN=361365485
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Int. J. Surg. 2010; 8: 336-341. Available from:. http://www.sciencedirect.com/science/article/pii/S1743919110000403
Author. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Clin. Liver Dis. 2018 Apr 1; 11: 81. Available from. https://doi.org/10.1002/cld.722
Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. Eur. J. Gastroenterol. Hepatol. 2019; 31: 613-617. Available from:. http://journals.lww.com/eurojgh/pages/default.aspx
Basu P, Shah N, Aloysius M, Junior R. Effect of vitamin E and alpha lipoic acid in nonalcoholic fatty liver disease: a randomized, placebo-controlled, open-label, prospective clinical trial (VAIN trial). Open J. Gastroenterol. 2014 Jan 1; 04: 199-207.
Bril F, Biernacki DM, Kalavalapalli S et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2019 Aug; 42: 1481-1488.
Dufour J, Oneta CM, Gonvers J et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2006; 4: 1537-1543. Available from. http://ovidsp.ovid.com/ovidweb.cgi?T=JS%26PAGE=reference%26D=emed9%26NEWS=N%26AN=44880031
Ekhlasi G, Mohammadi RK, Agah S et al. Do symbiotic and vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J. Res. Med. Sci. 2016; 21: 98. Available from:. http://jrms.mui.ac.ir/index.php/jrms/article/download/10516/5172
Magosso E, Ansari MA, Gopalan Y et al. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Nutr. J. 2014/01/01 2013; 12: 166.
Pervez MA, Khan DA, Ijaz A, Khan S. Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease. Turk. J. Gastroenterol. 2018/05/12 2018; 29: 170-176.
Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010 May; 362: 1675-1685.
Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 2009/05/09 2009; 29: 1184-1188.
Hoofnagle JH, Van Natta ML, Kleiner DE et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2013 Jul; 38: 134-143.
Taylor RS, Taylor RJ, Bayliss S et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020 Feb.
Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Version 5. The Cochrane Collaboration; 2019. Available from: www.handbook.cochrane.org
Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism 2015 Jan; 64: 60-78.
Friedman JM. Leptin and the regulation of body weigh. Keio J. Med. Japan 2011; 60: 1-9.
Ratziu V, Bugianesi E, Dixon J et al. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment. Pharmacol. Ther. 2007 Sep; 26: 821-830.
Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005 Jan; 142: 37-46.
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007 Feb; 297: 842-857.
Klein EA, Thompson IM Jr, Tangen CM et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011 Oct 12; 306: 1549-1556. Available from. https://www.ncbi.nlm.nih.gov/pubmed/21990298
Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010 Nov; 341: c5702.